A 4-gene immune-related biomarker signature (PVR, TNFRSF12A, IL21R, and SOCS1) may, together with other clinicopathological metrics, offer value as a means of assessing HNSCC patient prognosis [40]. This evidence concerns the gene TNFRSF12A and head and neck squamous cell carcinoma.